Table 3

Comparison of carrier and allele frequencies of HLA subtypes between CM-induced patients with SJS/TEN developing SOCs and normal controls

HLA-ACarrier frequencyAllele frequency
CaseControlP valueOR
(95% CI)
CaseControlP valueOR
(95% Cl)
FisherBonferroni correctionFisherBonferroni correction
A*02:067.7%
(1/13)
5.1%
(5/98)
0.5353.8% (1/26)3.1%
(6/196)
0.587
A*02:0738.5%
(5/13)
10.2%
(10/98)
0.016 0.155 5.56 (1.52 to 20.00)26.9% (7/26)5.1%
(10/196)
0.001 0.012 6.67 (2.33 to 20.00)
A*11:0130.8%
(4/13)
55.1%
(54/98)
0.14023.1% (6/26)31.6%
(62/196)
0.498
B*46:0130.77%
(6/13)
19.4%
(19/98)
0.07030.8% (8/26)10.2%
(20/196)
0.008 0.076 3.85 (1.52 to 10.00)
  • Bold type denotes p values with significance.

  • CM, cold medicine; HLA, human leucocyte antigen; SJS, Stevens-Johnson syndrome; SOCs, severe ocular complications; TEN, toxic epidermal necrolysis.